Decheng Capital

Portfolio Companies 2026 for Decheng Capital: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Decheng Capital accounts for 32 tracked companies with verified cap-table data, 32 of which disclose round sizes totalling $5.9B. The median disclosed raise is $147M, and the largest is ACELYRIN at $758M, ahead of Cue ($606M) and Mammoth Biosciences ($465M).

The names that recur most often on these portfolio cap tables are Decheng Capital (32 companies), Foresite Capital (6 companies), OrbiMed (5 companies), Samsara BioCapital (3 companies), Surveyor Capital (3 companies), Longitude Capital (3 companies). By latest disclosed round, the market skews Series C (9), Series A (7), Series B (6), Series D (3).

Best funded Decheng Capital companies

  1. ACELYRIN — $758M (latest: Series C)
  2. Cue — $606M (latest: Series C)
  3. Mammoth Biosciences — $465M (latest: Series D)
  4. Nalu Medical — $396M (latest: Growth)
  5. Aadi Bioscience — $265M (latest: IPO)
  6. Genapsys Inc. — $250M (latest: Series D)
  7. Syneron — $250M (latest: Series B)
  8. Ark Biosciences — $230M (latest: Series A)
  9. EpimAb Biotherapeutics — $219M (latest: Series C)
  10. VelosBio — $213M (latest: Seed)
  11. Upstream Bio — $200M (latest: Series A)
  12. CG Oncology — $200M (latest: IPO)
  13. Omniome — $160M (latest: Series C)
  14. Mindstrong Health — $160M (latest: Series C)
  15. Apexigen — $158M (latest: Series C)

Decheng Capital Global Healthcare GP, LLC — related firms and companies (56)

Decheng Capital Global Healthcare GP, LLC profile · All research reports